Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

The current role of chemotherapy in pancreatic carcinoma is limited, and progress in the treatment of this disease represents a significant challenge to medical oncology. The most promising drug under study is gemcitabine, a relatively new antimetabolite that represents an attractive candidate for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Neri, B, Cini, G, Doni, L, Fulignati, C, Turrini, M, Pantalone, D, Mini, E, De Luca Cardillo, C, Fioretto, L M, Ribecco, A S, Moretti, R, Scatizzi, M, Zocchi, G, Quattrone, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376146/
https://www.ncbi.nlm.nih.gov/pubmed/12189543
http://dx.doi.org/10.1038/sj.bjc.6600482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376146/
https://www.ncbi.nlm.nih.gov/pubmed/12189543
http://dx.doi.org/10.1038/sj.bjc.6600482

Ejemplares similares